Navigation Links
Endo and BioDelivery Sciences Provide Update on BEMA Buprenorphine Phase III Development Program
Date:9/4/2013

ificant because they utilized actual study data to confirm or adjust sample sizes, and importantly, maintain probability of a successful outcome," said Dr. Mark A. Sirgo, President and CEO of BDSI. "Data from the opioid naive study appear consistent with our original assumptions and no additional patients are required. This study has completed patient enrollment, and we continue to anticipate the study results early next year. We expect that the additional patients required for the opioid experienced trial will result in a slight adjustment to the timing for the completion of that study to mid 2014.  While no major impact is anticipated for the timing of the NDA submission, which was scheduled for the second half of 2014, more definitive timing will be provided when patient enrollment is completed."

About Endo

Endo Health Solutions Inc. (Endo) is a U.S.-based specialty healthcare company with four distinct business segments that are focused on branded and generic pharmaceuticals, devices and services, each providing quality products to our customers while improving the lives of patients. Through our operating companies – AMS, Endo Pharmaceuticals, HealthTronics and Qualitest – Endo is dedicated to finding solutions for the unmet needs of patients. Learn more at www.endo.com.

About BioDelivery Sciences International

BioDelivery Sciences International (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and addiction.

For more information visit

SOURCE Endo Pharmaceuticals Inc.; BioDelivery Sciences International, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of Second Quarter 2013 Financials
2. BioDelivery Sciences Announces Submission of NDA for BUNAVAIL
3. BioDelivery Sciences Announces the Hiring of Adrian Hepner, M.D. as Vice President of Clinical Research & Regulatory Affairs
4. BioDelivery Sciences to Present at the William Blair 33rd Annual Growth Stock Conference
5. BioDelivery Sciences to Present at the Jefferies 2013 Global Healthcare Conference
6. BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
7. BioDelivery Sciences Appoints Thomas W. DAlonzo to Board of Directors
8. BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its 2012 Annual Report
9. BioDelivery Sciences to Present at the 25th Annual ROTH Conference
10. BioDelivery Sciences to Host Buprenorphine Investor and Analyst Event
11. BioDelivery Sciences to Present at the 15th Annual BIO CEO and Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... Perrigo Company plc ("Perrigo") (NYSE: PRGO ... (NASDAQ: MYL ) shareholder vote regarding its planned ... of Mylan,s offer to Perrigo shareholders have always been, ... careful reflection of the value available to Perrigo shareholders, ... Mylan has allowed its shareholders to consider," said ...
(Date:8/28/2015)... The report "Eubiotics Market by Type (Probiotics, Prebiotics, ... Aquaculture), & by Region ( North America , ... and Rest of the World) - Global Trends and Forecast ... was valued at USD 4.62 Billion in 2014 and is ... CAGR of 7.4% from 2015 to 2020. ...
(Date:8/27/2015)... Mass. , Aug. 27, 2015  A ... the KSSTA Knee Journal, compared the Arthrosurface HemiCAP® ... Arthroplasty design, versus an "onlay" design implant for ... similar improvements in function and pain scores, none ... progression of osteoarthritis (OA). However, 53% of the ...
Breaking Medicine Technology:Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 2Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 3Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 4Perrigo Confident Its Shareholders Will Reject Mylan's Value Destructive Transaction 5Eubiotics Market Worth 7.05 Billion USD by 2020 2Eubiotics Market Worth 7.05 Billion USD by 2020 3Eubiotics Market Worth 7.05 Billion USD by 2020 4Eubiotics Market Worth 7.05 Billion USD by 2020 5Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 2Study Demonstrates Dramatic Reduction in Progression of Osteoarthritis with the Arthrosurface "Inlay" Patellofemoral Implant Design Compared to Traditional "Onlay" Implant 3
... fundamental traits of a,tumor – how it avoids ... according to researchers from the,University of Southern California. ... cancers, indicate that,a technique for determining a tumor’s ... cancers. , ,In the July 1 issue ...
... - Nymox,Pharmaceutical Corporation (NASDAQ: NYMX) today announced ... of NX-1207 for,benign prostatic hyperplasia (BPH) will ... the American Urological Association Meeting in,Boston in ... clinical,research investigators from U.S. clinical trials of ...
Cached Medicine Technology:Researchers Discover Method for Identifying How Cancer Evades the,Immune System 2Researchers Discover Method for Identifying How Cancer Evades the,Immune System 3Clinical Data From Nymox BPH Drug To Be Presented at American,Urological Association Meeting 2
(Date:8/28/2015)... IL (PRWEB) , ... August 28, 2015 , ... With ... benefit concert returned for the second year to the Adams County Fairgrounds in Mendon, ... was held to raise money to support music education in the underfunded school districts ...
(Date:8/28/2015)... ... ... The 6th Annual Survivor in the City, Chicago silent auction and cocktail ... its cadre of widespread support—an official letter of support and gratitude from the Mayor ... and the University of Illinois at Chicago’s Department of Neurosurgery, the Brain Aneurysm Foundation ...
(Date:8/28/2015)... ... ... Frequentz ” was featured on NewsWatch as part of its monthly AppWatch, which takes ... and Windows. Joe Toohey, the host of AppWatch and technology expert, conducted the app ... from beginning to end. , Businesses benefit greatly from having the ability to track ...
(Date:8/28/2015)... ... August 28, 2015 , ... ... Veterans Award, honoring military veterans leading in business. Mr. Troy Mizell, Chairman ... , The inaugural Nashville Business Journal's 2015 Veterans Awards will recognize Nashville military ...
(Date:8/28/2015)... ... August 28, 2015 , ... The Quatela Center for Plastic Surgery ... first and only nonsurgical product approved by the Food and Drug Administration to eliminate ... and Dr. William Koenig are among the premier cosmetic surgeons in Rochester ...
Breaking Medicine News(10 mins):Health News:Best Drug Rehabilitation Interviews Country-Rock Duo Highway Run at the 2015 "Music With A Mission" Benefit Concert 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 2Health News:Chicago Mayor Pens Official Support of Annual Survivor in the City Event Benefitting Brain Aneurysm Foundation 3Health News:Track Product Movement from Beginning to End with Frequentz 2Health News:MyGenetx Board Member Receives Veterans Award 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 2Health News:Non-surgical Treatment to Get Rid of The "Double Chin," Kybella™, Now Available at the Quatela Center for Plastic Surgery 3
... closed, American cardiologists say , , WEDNESDAY, July 2 (HealthDay ... to adrenaline did not improve survival among people who ... American cardiologists said the finding does not rule out ... report comes from a group, primarily French, that several ...
... 2 Hanger Orthopedic,Group, Inc. (NYSE: HGR ... Poor,s,Rating Services revised its outlook for Hanger Orthopedic ... Hanger,s corporate credit,rating at "B." "The outlook revision ... an improved financial risk profile," said,Standard & Poor,s ...
... medicine specialist, John Albright, MD, will join three other physicians as ... Fame inductee. , ... Orlando, Florida (PRWEB) July 2, ... will join three other physicians as a 2008 American Orthopaedic ...
... Ambulatory Services of,America, Inc. announced the acquisition of ... from Affiliated Hospitals Dialysis Center.,Affiliated Hospitals Dialysis Center ... and St. John,s Mercy Health System. Prior,to the ... 300 patients,through the three outpatient dialysis centers and ...
... Larry Minnix, President & CEO, American Association of,Homes ... of the Medicare Therapy,Caps Exceptions Process, WASHINGTON, ... Minnix, President & CEO, American Association of Homes ... the Medicare Therapy Caps,Exceptions Process:, "Medicare beneficiaries ...
... Ambulatory Services of,America, Inc. announced the formation of ... to provide outpatient radiation oncology services. ROSA,of North ... Radiation,Oncology Services of America, and some of the ... North Dallas will own and operate Northpoint,Cancer Center ...
Cached Medicine News:Health News:Two-Drug Treatment Didn't Improve Cardiac Arrest Survival Rates 2Health News:Two-Drug Treatment Didn't Improve Cardiac Arrest Survival Rates 3Health News:Hanger Orthopedic Group, Inc. Receives Positive Outlook from Standard & Poor's Rating Services 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 3Health News:Ambulatory Services of America, Inc. Announces the Acquisition of Dialysis Operations in St. Louis, Missouri 2Health News:AAHSA Statement: Therapy Caps Ration Care 2Health News:Ambulatory Services of America, Inc. Announces Joint Venture to Operate Radiation Oncology Facility in Dallas, Texas 2
3 mm, 130 degree upwards cutting, detachable....
Aaron 950 is a high frequency desiccator with cut....
Sabre 180 is a powerful niche generator....
The Sabre 2400 provides high power performance and key user features to meet today's demanding electrosurgical needs. It is an ideal general-purpose electrosurgical generator....
Medicine Products: